<!doctype html>
<html amp lang="en">
  <head>
    <meta charset="utf-8"> <title>FDA approves Flexion’s osteoarthritis treatment - The Boston Globe</title>
	<meta name="eomportal-instanceid" content="217"/>
<meta name="eomportal-id" content="1472798"/>
<meta name="eomportal-loid" content="4.4.843534806"/>
<meta name="eomportal-uuid" content="4500186c-aacf-11e7-b104-74c00c2dc2bd"/>
<meta name="eomportal-lastUpdate" content="Tue Oct 10 02:25:44 EDT 2017"/>
<script async custom-element="amp-social-share" src="https://cdn.ampproject.org/v0/amp-social-share-0.1.js"></script>
    <link rel="canonical" href="http://www.bostonglobe.com/business/2017/10/06/fda-approves-flexion-osteoarthritis-treatment/rcNoeMy4QKBw45SOcMK3jP/story.html" />
    <meta name="viewport" content="width=device-width,minimum-scale=1,initial-scale=1">
    <style amp-custom>
    	@font-face {
  font-family: "Miller Headline Roman";
  src: url("/font/MillerHeadline/4d418a22-c167-4249-be16-b789d221d18d-2.eot") format("eot");
  src: url("/font/MillerHeadline/4d418a22-c167-4249-be16-b789d221d18d-2.eot?iefix") format("eot"), url("/font/MillerHeadline/4d418a22-c167-4249-be16-b789d221d18d-3.woff") format("woff"), url("/font/MillerHeadline/4d418a22-c167-4249-be16-b789d221d18d-1.ttf") format("truetype"), url("/font/MillerHeadline/4d418a22-c167-4249-be16-b789d221d18d-1.woff2") format("woff2"), url("/font/MillerHeadline/4d418a22-c167-4249-be16-b789d221d18d-4.svg") format("svg");
}

@font-face {
  font-family: "Miller Headline Bold";
  src: url("/font/MillerHeadline-Bold/3c91bd2d-bc82-4bba-944e-ab157bcdeae2-2.eot") format("eot");
  src: url("/font/MillerHeadline-Bold/3c91bd2d-bc82-4bba-944e-ab157bcdeae2-2.eot?iefix") format("eot"), url("/font/MillerHeadline-Bold/3c91bd2d-bc82-4bba-944e-ab157bcdeae2-3.woff") format("woff"), url("/font/MillerHeadline-Bold/3c91bd2d-bc82-4bba-944e-ab157bcdeae2-1.ttf") format("truetype"), url("/font/MillerHeadline-Bold/MHB.woff2") format("woff2"), url("/font/MillerHeadline-Bold/3c91bd2d-bc82-4bba-944e-ab157bcdeae2-4.svg") format("svg");
}

@font-face {
  font-family: "Benton Sans Bold";
  src: url("/font/BentonSans-Bold/79e52a98-c6b6-4ed0-a074-409e1de09fd6-2.eot") format("eot");
  src: url("/font/BentonSans-Bold/79e52a98-c6b6-4ed0-a074-409e1de09fd6-2.eot?iefix") format("eot"), url("/font/BentonSans-Bold/79e52a98-c6b6-4ed0-a074-409e1de09fd6-3.woff") format("woff"), url("/font/BentonSans-Bold/79e52a98-c6b6-4ed0-a074-409e1de09fd6-3.woff2") format("woff2"), url("/font/BentonSans-Bold/79e52a98-c6b6-4ed0-a074-409e1de09fd6-1.ttf") format("truetype"), url("/font/BentonSans-Bold/79e52a98-c6b6-4ed0-a074-409e1de09fd6-4.svg") format("svg");
}

@font-face {
  font-family: "BentonSansRegular";
  src: url("/font/BentonSansRegular/BentonSansRegular.eot") format("eot");
  src: url("/font/BentonSansRegular/BentonSansRegular.eot?iefix") format("eot"), url("/font/BentonSansRegular/BentonSansRegular.woff") format("woff"), url("/font/BentonSansRegular/BentonSansRegular.woff2") format("woff2"), url("/font/BentonSansRegular/BentonSansRegular.ttf") format("truetype"), url("/font/BentonSansRegular/BentonSansRegular.svg") format("svg");
}

body {
  font-family: Helvetica, san-serif;
  color: #000000;
}

.header {
  background-color: #000000;
  height: 50px;
  position: relative;
  margin-bottom: 20px;
}

.header .subscribe-link {
  text-decoration: none;
  font-size: 10px;
  letter-spacing: 0px;
  color: #ffffff;
  float: right;
  margin-top: 20px;
  margin-right: 5%;
}

.header-logo {
  position: absolute;
  margin: auto;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  margin-top: 15px;
}

.dek {
  margin-top: 5px;
  font-family: "Miller Headline Roman", Times, serif;
  font-size: 18px;
  color: #444444;
  letter-spacing: 0px;
  line-height: 24px;
}

.footer {
  background-color: #ededed;
  height: 100px;
}

.footer .bg-copy {
  text-align: center;
  font-size: 10px;
  color: #999999;
  margin-bottom: 0;
}

.footer-menu {
  list-style: none;
  padding: 25px 0 0 0;
  text-align: center;
}

.footer-menu li {
  display: inline-block;
  text-align: center;
}

.footer-menu li a, .footer-menu li a:visited {
  line-height: 14px;
  text-decoration: none;
  margin: 0 auto;
  font-size: 10px;
  border-left: 1px solid #eaeaea;
  padding: 0 3px 0 7px;
  color: #1588AB;
}

.footer-menu li:first-child a {
  border-left: 0 solid white;
}

.hed-cat {
  margin: 0 auto;
  font-size: 11px;
  color: #b50303;
  letter-spacing: 0px;
  padding: 5px 0 3px;
}

h1 {
  color: #000000;
  letter-spacing: 0px;
  line-height: 36px;
  margin: 0 0 5px 0;
  font-weight: normal;
  font-family: "Miller Headline Bold", Times, serif;
  font-size: 30px;
}

h2.subhead {
  color: #444444;
  letter-spacing: 0px;
  line-height: 24px;
  margin-bottom: -12px;
  padding-top: 10px;
  font-family: Helvetica, san-serif;
  font-size: 18px;
}

.byline {
  color: #999999;
  letter-spacing: 0px;
  font-size: 14px;
}

.byline .author {
  color: #000000;
  padding-right: 3px;
}

.byline .author a,
.byline .author a:visited {
  color: #000000;
  text-decoration: none;
}

.byline time {
  color: #000000;
}

.caption {
  color: #444444;
  letter-spacing: 0px;
  line-height: 18px;
  margin: 0 0 18px;
  font-size: 13px;
}

.credit {
  margin: 10px 0 5px;
  width: 100%;
  color: #999999;
  letter-spacing: 0px;
  text-transform: uppercase;
  text-align: right;
  font-size: 10px;
}

.creator, .caption {
  clear: both;
}

time {
  display: block;
  padding-top: 5px;
  font-size: 14px;
  letter-spacing: 0px;
}

.author {
  font-family: Helvetica, san-serif;
  font-size: 14px;
  letter-spacing: 0px;
}

.subhed {
  font-family: Helvetica, san-serif;
  font-size: 20px;
  letter-spacing: 0;
  line-height: 28px;
}

.body-copy {
  font-family: Georgia, serif;
  font-size: 16px;
  letter-spacing: 0;
  line-height: 28px;
}

.body-copy a,
.body-copy a:visited {
  color: #1588AB;
  text-decoration: underline;
}

.figcaption {
  margin-bottom: 20px;
  font-size: 13px;
  color: #444444;
  letter-spacing: 0;
  line-height: 18px;
  font-family: Helvetica, san-serif;
}

.figcaption .credit {
  float: none;
  margin-top: 5px;
}

.figcaption p {
  width: 100%;
  margin-top: 5px;
}

.author-info {
  border-top: 1px solid #eaeaea;
  padding-bottom: 20px;
  font-family: Georgia, serif;
  font-size: 14px;
  color: #000000;
  letter-spacing: 0px;
  line-height: 24px;
}

.author-info a, .author-info a:visited {
  color: #1588AB;
}

.inline-newsletter {
  height: 48px;
  padding-top: 20px;
  background-color: #ededed;
  font-size: 14px;
  font-family: "BentonSansRegular", Arial, sans-serif;
  text-align: center;
}

.inline-newsletter .bold {
  font-family: "Benton Sans Bold", "Arial Black", sans-serif;
}

.inline-newsletter .arrow {
  display: inline;
  color: #1588AB;
}

.inline-newsletter a {
  display: inline-block;
  color: #1588AB;
}

.ad {
  text-align: center;
}

.article-more a {
  display: block;
  text-decoration: none;
  color: #999999;
  font-size: 11px;
  font-family: Helvetica, san-serif;
  text-align: center;
  text-transform: uppercase;
}

.iframe-wrapper {
  height: 0px;
  overflow: hidden;
}

.iframe-wrapper .bold {
  font-family: "Miller Headline Bold", Times, serif;
}

.iframe-wrapper a {
  text-decoration: underline;
}

/*
Amp-column should be used to center elements.
Other selectors are for elements that can not be targeted at the .jpt level.
 */
.amp-column,
.byline,
p,
h2.subhead,
.figcaption {
  margin-left: auto;
  margin-right: auto;
  width: 90%;
}

.share-button {
  margin-right: 15px;
  margin-bottom: 20px;
}

.share-button--facebook {
  background-size: 35px;
}

.share-button--twitter {
  background-size: 28px;
}

/* Recirculation module */
.recommended {
  width: 100%;
}

.recommended__header {
  font-size: 20px;
  margin-left: 5%;
}

.recommended__items {
  margin: 0;
  padding: 0;
  list-style: none;
}

.recommended__item {
  position: relative;
  width: 90%;
  margin: 0 auto;
  padding: 20px 0;
  border-top: 1px solid #eaeaea;
}

.recommended__item--sponsored {
  padding: 20px 5%;
  background-color: #eaeaea;
}

.recommended__item-overline {
  font-size: 11px;
  color: #b50303;
}

.recommended__item-overline--sponsored {
  color: #000000;
}

.recommended__item-sponsor-name {
  color: #de7d0b;
  text-transform: uppercase;
}

.recommended__link {
  text-decoration: none;
  color: #444444;
}

.recommended__title {
  margin: 0 0 5px;
  font-weight: normal;
  font-family: "Miller Headline Bold", Times, serif;
}

.recommended__body {
  font-size: 13px;
  font-family: Georgia, serif;
  line-height: 18px;
}

.recommended__body p {
  margin: 0;
  display: inline;
}

.recommended__more {
  margin-left: 3px;
  color: #1588AB;
}

.recommended__helper-tip-text {
  width: 200px;
  display: none;
  z-index: 100;
  position: absolute;
  top: 35px;
  right: 20px;
  padding: 10px;
  color: #ffffff;
  background-color: rgba(10, 10, 10, 0.8);
  line-height: 15px;
}

.recommended__helper-tip:hover + span.recommended__helper-tip-text {
  display: block;
}

.recommended__helper-tip {
  float: right;
  text-decoration: none;
  color: #999999;
  font-family: Georgia, serif;
  font-style: italic;
}
</style>

    <script type="application/ld+json">
      {
        "@context": "http://schema.org",
        "@type": "NewsArticle",
        "mainEntityofPage": "http://www.bostonglobe.com/business/2017/10/06/fda-approves-flexion-osteoarthritis-treatment/rcNoeMy4QKBw45SOcMK3jP/story.html",
        "headline": "FDA approves Flexion’s osteoarthritis treatment",
        "description": "Burlington biotech’s injectable drug for knee pain could generate more than $1 billion in annual sales. ",
        "dateModified": "2017-10-06T19:46:09Z",
        "datePublished": "2017-10-06T19:46:09Z",
	    "image": {
	        "@type": "ImageObject",
	        "url": "https://c.o0bg.com/$configurationURI/Framework/images/logo-bg.jpg",
            "width": 960,
            "height": 640
	    },
	    "author": {
	        "@type": "Person",
	        "name": "By Jonathan Saltzman"
	    },
		"publisher": {
		        "@type": "Organization",
		        "name": "The Boston Globe",
		        "logo": {
		            "@type": "ImageObject",
		            "url": "https://www.bostonglobe.com/img/siteLogos/amp-logo.png",
		            "width": 600,
		            "height": 60
		        }
		  }
      }
    </script>
    <style amp-boilerplate>body{-webkit-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-moz-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-ms-animation:-amp-start 8s steps(1,end) 0s 1 normal both;animation:-amp-start 8s steps(1,end) 0s 1 normal both}@-webkit-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-moz-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-ms-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-o-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}</style><noscript><style amp-boilerplate>body{-webkit-animation:none;-moz-animation:none;-ms-animation:none;animation:none}</style></noscript>
    <script async src="https://cdn.ampproject.org/v0.js"></script>
    <script async custom-element="amp-iframe" src="https://cdn.ampproject.org/v0/amp-iframe-0.1.js"></script>
  </head>
  <body>
    <div class="header">
	<a href="//www.bostonglobe.com"><amp-img class="header-logo" src="/rw/img/bglobe-logo-white.png" alt="" height="19" width="140"></amp-img></a>
  <a class="subscribe-link" href="//subscribe.bostonglobe.com/B9385/?p1=BGAMPHeader_DigitalSubscription">SUBSCRIBE</a>
</div>
<div class="iframe-wrapper">
      <amp-iframe width=5 height=5 sandbox="allow-scripts allow-same-origin" layout="fixed" frameborder="0" src="https://c.o0bg.com/Fragment/SysConfig/WebPortal/BostonGlobe/Framework/skins/leaf/google_amp/amp_analytics.jpt?uuid=ffdf618e-aace-11e7-9c9a-79fc030231c7"><div placeholder></div></amp-iframe></div>
    <h1 class="amp-column">FDA approves Flexion’s osteoarthritis treatment
</h1>
<p class="no-dek"></p>
	<div class="byline">
	<b class="author"><!---->By <a class="" title="More Stories by Jonathan Saltzman" href="/staff/saltzman" rel="author"><span itemprop="name">Jonathan Saltzman</span></a></b>
	Globe Staff  &nbsp;
	<time itemprop="datePublished" datetime="2017-10-06 19:46">October 06, 2017</time>
	<p></p>
	<p></p>
</div><div class="body-copy">
	<!----><p>Hobbled by knee pain? </p><p>Federal regulators on Friday approved a new drug for osteoarthritis in the knee that its maker &mdash; Burlington-based Flexion Therapeutics Inc. &mdash; says provides substantially longer relief than treatments already on the market and could become a blockbuster medicine.   </p><p class="skip-nav article-more">
	<a>Advertisement</a>
</p>

<div class="ad">
	<amp-ad width="300" height="250" type="doubleclick" layout="fixed"
		data-slot="/61381659/bostonglobe.com_amp/business"
		json='{"targeting":{"pos":["bigbox1","atf"],"pgtype":"article","s1":"bostonglobe.com","s2":"business","pageurl":"_business_2017_10_06_fda-approves-flexion-osteoarthritis-treatment_rcNoeMy4QKBw45SOcMK3jP_story_html","meta":"flexion,fda,zilretta,osteoarthritis,knee","test":""}}'>
	</amp-ad>
</div>   
<p>The Food and Drug Administration approved Flexion&rsquo;s Zilretta, an inflammation-suppressing non-opioid steroid that is delivered through an injection. Although injectables have been marketed for decades, Zilretta uses a novel delivery system. Small particles known as microspheres gradually release the medicine in patients&rsquo; joints over an extended period. The company says it provides relief for three months after a single dose, in contrast with other steroid injections that typically relieve pain for only two to four weeks.</p><amp-iframe width="auto" height="220" sandbox="allow-scripts allow-same-origin allow-forms" layout="fixed-height" frameborder="0" src="https://c.a0bg.com/Fragment/SysConfig/WebPortal/BostonGlobe/Framework/skins/leaf/story/dynamic_newsletter.jpt?section=%2fbusiness&googleArticle=yes"></amp-iframe>

<p>&ldquo;This product has the potential to be transformative,&rdquo; said Flexion chief executive Michael Clayman, a physician. &ldquo;We&rsquo;re thrilled.&rdquo;</p><p>More than 15 million Americans were diagnosed with osteoarthritis of the knee last year. Over 4 million such patients get conventional steroid injections each year, Clayman said. About half of  patients with the painful, progressive condition ultimately seek knee replacements.</p><p>Clayman said Flexion will announce a price for the drug within days, but he expects it to be about $500 for each dose. Patients would receive injections in their knees at the office of an orthopedic specialist, a procedure that would take less than a minute.</p><p>Industry experts have predicted that the drug could eventually generate $600 million to $1.4 billion annually.</p><p class="skip-nav article-more">
	<a>Advertisement</a>
</p>

<div class="ad">
	<amp-ad width="300" height="250" type="doubleclick" layout="fixed"
		data-slot="/61381659/bostonglobe.com_amp/business"
		json='{"targeting":{"pos":["bigbox2","btf"],"pgtype":"article","s1":"bostonglobe.com","s2":"business","pageurl":"_business_2017_10_06_fda-approves-flexion-osteoarthritis-treatment_rcNoeMy4QKBw45SOcMK3jP_story_html","meta":"flexion,fda,zilretta,osteoarthritis,knee","test":""}}'>
	</amp-ad>
</div>   
<p>Founded 10 years ago by Clayman and another physician &mdash; both veterans of the pharmaceutical giant Eli Lilly and Co. &mdash; Flexion has grown to 140 employees and is expected to reach about 270 by the end of the year after adding sales staff.</p><p>The FDA granted Zilretta fast-track status in 2015, a designation given to drugs that can offer significant improvement over therapies already on the market. </p><p>Knee osteoarthritis has become twice as common since 1950, according to a recent study in the journal Proceedings of the National Academy of Sciences and now affects about one in five American adults 45 or older. The investigators examined knee joints in skeletons dating back thousands of years.</p><p>Although some medical specialists have attributed the increase in knee osteoarthritis to the fact that people are living longer and obesity is more common, the study said those factors alone don&rsquo;t account for the surge. </p><p>Among the other potential factors the authors recommended be studied are whether a decline in physical activity over the past 60 years has led to thinner cartilage in joints, whether modern diets rich in refined carbohydrates have worsened chronic mild inflammation, and whether walking on hard pavement exacerbates problems.</p><p>Flexion isn&rsquo;t the only local biotech developing drugs for osteoarthritis in knees.</p><p>Centrexion Therapeutics Corp., led by former Pfizer Inc. chief executive Jeffrey B. Kindler, said last December that it was moving from Baltimore to Boston to speed its own pipeline of experimental pain drugs. </p><p>Its lead drug candidate is a synthetic form of capsaicin &mdash; a medicine derived from the chili plant &mdash; that also treats such knee pain, but uses a different approach. It binds to receptors at the end of pain fibers to stop the signal sent to the brain and spinal cord.</p></div>
<div class="author-info amp-column">
		<!----><i>
<br>Jonathan Saltzman can be reached at <a class="a" href="mailto:jsaltzman@globe.com">jsaltzman@globe.com.</a></i></div>
<div class="amp-column">
	<amp-social-share type="facebook"
	    data-param-app_id="527718554097657" data-param-href="http://www.bostonglobe.com/business/2017/10/06/fda-approves-flexion-osteoarthritis-treatment/rcNoeMy4QKBw45SOcMK3jP/story.html?s_campaign=bostonglobe:social:googleamp:sharetools" class="share-button share-button--facebook">
	</amp-social-share>
	<amp-social-share type="twitter"
		data-param-url="http://www.bostonglobe.com/business/2017/10/06/fda-approves-flexion-osteoarthritis-treatment/rcNoeMy4QKBw45SOcMK3jP/story.html?s_campaign=bostonglobe:social:googleamp:sharetools" class="share-button share-button--twitter">
	</amp-social-share>
	<amp-social-share type="email"
		data-param-body="http://www.bostonglobe.com/business/2017/10/06/fda-approves-flexion-osteoarthritis-treatment/rcNoeMy4QKBw45SOcMK3jP/story.html?s_campaign=bostonglobe:social:googleamp:sharetools" class="share-button">
	</amp-social-share>
</div>

<div class="recommended">
	<h2 class="recommended__header">More Stories</h2>
	<ul class="recommended__items">
		<li class="recommended__item recommended--tease" data-loid="4.4.912400582">
  <a href="/business/2017/10/09/homeowner-deck-nightmare/C7IN6Ej7pNmNASrIz7ormI/story.html?p1=AMP_Recirculation_Pos1" class="recommended__link">
    <div class="recommended__content">
      <span class="recommended__item-overline">THE FINE PRINT | Sean P. Murphy</span>
      <h2 class="recommended__title">A homeowner’s deck nightmare</h2>
      <div class="recommended__body">
        <p>A $25,000 contract with Lowe’s left a Newton woman with no deck all summer long. </p><span class="recommended__more">Continue reading &raquo;</span>
      </div>
    </div>
  </a>
</li>
<li class="recommended__item recommended--tease" data-loid="4.4.913867457">
  <a href="/business/2017/10/09/boston-pros-and-cons-surround-amazon-bid/GJCbQ6jVCA4FBMLtoUCPHO/story.html?p1=AMP_Recirculation_Pos2" class="recommended__link">
    <div class="recommended__content recommended__content--no-overline">
      <span class="recommended__item-overline"></span>
      <h2 class="recommended__title">Boston is a city of two tales with its Amazon bid</h2>
      <div class="recommended__body">
        <p>Boston has pros and cons in its efforts to woo Amazon, and which version of the city the company’s executives see may determine the outcome. </p><span class="recommended__more">Continue reading &raquo;</span>
      </div>
    </div>
  </a>
</li>
<li class="recommended__item recommended--tease" data-loid="3.3.1274427313">
  <a href="/business/2014/10/11/cable/NEBNVPfcYSrCy1TqdtyYgK/story.html?p1=AMP_Recirculation_Pos3" class="recommended__link">
    <div class="recommended__content recommended__content--no-overline">
      <span class="recommended__item-overline"></span>
      <h2 class="recommended__title">How one couple beat the cable company</h2>
      <div class="recommended__body">
        <p>A telecommunications diet plan based on four principles led to nearly $1,800 a year in savings.</p><span class="recommended__more">Continue reading &raquo;</span>
      </div>
    </div>
  </a>
</li>
<li class="recommended__item recommended--tease" data-loid="4.4.230868591">
  <a href="/business/2017/09/08/have-you-been-hacked-what-after-equifax-data-theft/GWZ7jbpWQTb7o2xuOMuMOL/story.html?p1=AMP_Recirculation_Pos4" class="recommended__link">
    <div class="recommended__content recommended__content--no-overline">
      <span class="recommended__item-overline"></span>
      <h2 class="recommended__title">Have you been hacked? What to do after the Equifax data theft</h2>
      <div class="recommended__body">
        <p>These are the steps you need to take to protect your identity.</p><span class="recommended__more">Continue reading &raquo;</span>
      </div>
    </div>
  </a>
</li>
<li class="recommended__item recommended--tease" data-loid="1.0.1784658463">
  <a href="/business/2012/06/09/harvard-researcher-says-children-learn-racism-quickly/gWuN1ZG3M40WihER2kAfdK/story.html?p1=AMP_Recirculation_Pos5" class="recommended__link">
    <div class="recommended__content">
      <span class="recommended__item-overline">Diversity Boston</span>
      <h2 class="recommended__title">Racism learned</h2>
      <div class="recommended__body">
        <p>New research suggests prejudices may form at a much earlier age, but it also offers hope that biases can be unlearned.</p><span class="recommended__more">Continue reading &raquo;</span>
      </div>
    </div>
  </a>
</li>
<li class="recommended__item recommended--tease" data-loid="4.4.911650852">
  <a href="/business/2017/10/09/cargurus-debuts-stock-market-thursday/OhsLUcPnTia1rTdv0J0W0K/story.html?p1=AMP_Recirculation_Pos6" class="recommended__link">
    <div class="recommended__content recommended__content--no-overline">
      <span class="recommended__item-overline"></span>
      <h2 class="recommended__title">CarGurus debuts on stock market Thursday</h2>
      <div class="recommended__body">
        <p>CarGurus Inc., the Cambridge online automotive shopping company, is set to go public on Thursday.</p><span class="recommended__more">Continue reading &raquo;</span>
      </div>
    </div>
  </a>
</li>
<li class="recommended__item recommended--tease" data-loid="4.4.892006481">
  <a href="/business/2017/10/08/dove-that-shows-black-woman-turning-herself-white-sparks-consumer-backlash/6pBdI5BBCghteK2FID1UNJ/story.html?p1=AMP_Recirculation_Pos7" class="recommended__link">
    <div class="recommended__content recommended__content--no-overline">
      <span class="recommended__item-overline"></span>
      <h2 class="recommended__title">Dove ad that shows a black woman turning herself white sparks consumer backlash</h2>
      <div class="recommended__body">
        <p>The ire-inducing advertisement — a static compilation of four photos — was released Saturday.</p><span class="recommended__more">Continue reading &raquo;</span>
      </div>
    </div>
  </a>
</li>
<li class="recommended__item recommended--tease" data-loid="4.1.2493679346">
  <a href="/business/2016/02/19/the-war-for-tech-talent-escalates/ejUSbuPCjPLCMRYlRZIKoJ/story.html?p1=AMP_Recirculation_Pos8" class="recommended__link">
    <div class="recommended__content recommended__content--no-overline">
      <span class="recommended__item-overline"></span>
      <h2 class="recommended__title">The war for tech talent escalates</h2>
      <div class="recommended__body">
        <p>Executives in Massachusetts say a lack of skilled technology workers is hindering their ability to expand and innovate.   </p><span class="recommended__more">Continue reading &raquo;</span>
      </div>
    </div>
  </a>
</li>
<li class="recommended__item recommended--tease" data-loid="4.4.844826413">
  <a href="/business/2017/10/06/new-chief-executive-shakes-management-team/P8yRDCizhBfpk7aWKJzRiJ/story.html?p1=AMP_Recirculation_Pos9" class="recommended__link">
    <div class="recommended__content recommended__content--no-overline">
      <span class="recommended__item-overline"></span>
      <h2 class="recommended__title">GE continues its makeover as longtime execs depart</h2>
      <div class="recommended__body">
        <p>John Flannery is separating himself from his predecessor with a management shake-up that will see three top executives step down. </p><span class="recommended__more">Continue reading &raquo;</span>
      </div>
    </div>
  </a>
</li>
</ul>
</div>
<div class="footer">
  <ul class="footer-menu">
    <li class="footer-li"><a href="//www.bostonglobe.com/">HOME</a></li>
    <li class="footer-li"><a href="//bostonglobe.custhelp.com/app/home?p1=BGFooter">CONTACT</a></li>
    <li class="footer-li"><a href="//www.bostonglobe.com/tools/help/privacy">PRIVACY POLICY</a></li>
    <li class="footer-li"><a href="//subscribe.bostonglobe.com/B9385/?p1=BGAMPFooter_DigitalSubscription">SUBSCRIBE</a></li>
  </ul>
  <p class="bg-copy">&copy; 2017 Boston Globe Media Partners, LLC..</p>
</div>
</body>
</html>

